Find Triheptanoin manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

0

JDMF

0

EU WC

0

KDMF

0

VMF

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Europe

0

Australia

0

South Africa

0

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

GLOBAL SALES INFORMATION

Regulatory FDF Prices

NA

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 620-67-7, Propane-1,2,3-triyl triheptanoate, Trienanthoin, Trioenanthoin, Glyceryl triheptanoate, Glycerol triheptanoate
Molecular Formula
C24H44O6
Molecular Weight
428.6  g/mol
InChI Key
PJHKBYALYHRYSK-UHFFFAOYSA-N
FDA UNII
2P6O7CFW5K

Triheptanoin
Triheptanoin is a source of heptanoate fatty acids, which can be metabolized without the enzymes of long chain fatty acid oxidation. In clinical trials, patients with long chain fatty acid oxidation disorders (lc-FAODs) treated with triheptanoin are less likely to develop hypoglycemia, cardiomyopathy, rhabdomyolysis, and hepatomegaly. Complications in lc-FAOD patients are reduced from approximately 60% to approximately 10% with the addition of triheptanoin. Triheptanoin was granted FDA approval on 30 June 2020.
1 2D Structure

Triheptanoin

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2,3-di(heptanoyloxy)propyl heptanoate
2.1.2 InChI
InChI=1S/C24H44O6/c1-4-7-10-13-16-22(25)28-19-21(30-24(27)18-15-12-9-6-3)20-29-23(26)17-14-11-8-5-2/h21H,4-20H2,1-3H3
2.1.3 InChI Key
PJHKBYALYHRYSK-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CCCCCCC(=O)OCC(COC(=O)CCCCCC)OC(=O)CCCCCC
2.2 Other Identifiers
2.2.1 UNII
2P6O7CFW5K
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Glyceroltriheptanoate

2. Glyceryl Triheptanoate

2.3.2 Depositor-Supplied Synonyms

1. 620-67-7

2. Propane-1,2,3-triyl Triheptanoate

3. Trienanthoin

4. Trioenanthoin

5. Glyceryl Triheptanoate

6. Glycerol Triheptanoate

7. Triheptanoic Glyceride

8. Heptanoin, Tri-

9. Ux007

10. Dermofeel Tc 7

11. Dojolvi

12. Propane-1,2,3-triyl Trisheptanoate

13. 2,3-di(heptanoyloxy)propyl Heptanoate

14. Dub Thg

15. Heptanoic Acid, 1,2,3-propanetriyl Ester

16. Dermofeel Tc-7

17. Ux-007

18. Radiamuls 2375

19. Lanol 37 T

20. Triheptanoin [usan]

21. 2p6o7cfw5k

22. 3-02-00-00769 (beilstein Handbook Reference)

23. Heptanoic Acid, 1,1',1''-(1,2,3-propanetriyl) Ester

24. Triheptanoin (usan)

25. Triheptylin

26. 1,2,3-propanetriyl Triheptanoate

27. Glyceroltriheptanoate

28. Brn 1807724

29. Lanol 37t

30. Einecs 210-647-2

31. Unii-2p6o7cfw5k

32. Trienantin

33. Dojolvi (tn)

34. Glycerol Trienanthate

35. Glyceryl Trienanthate

36. Triheptanoin [mi]

37. Triheptanoin [inn]

38. Ec 210-647-2

39. Triheptanoin [inci]

40. Schembl525618

41. Triheptanoin [who-dd]

42. Glycerol Trienanthate, >=94%

43. Chembl4297585

44. Gtpl11431

45. Dtxsid40862306

46. Propane-1,2,3-triyltriheptanoate

47. Triheptanoin [orange Book]

48. Zinc4521897

49. Ind106011

50. Mfcd00042910

51. Ux 007

52. 1r,2s-(-)-norephedrinehydrochloride

53. Cs-w013852

54. Db11677

55. Hy-w013136

56. Ind 106011

57. Ind-106011

58. Ind106011; Ux007

59. Ls-15081

60. Ft-0757070

61. D11465

62. A868568

63. Q414576

64. W-109093

2.4 Create Date
2005-08-08
3 Chemical and Physical Properties
Molecular Weight 428.6 g/mol
Molecular Formula C24H44O6
XLogP37.3
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count6
Rotatable Bond Count23
Exact Mass428.31378912 g/mol
Monoisotopic Mass428.31378912 g/mol
Topological Polar Surface Area78.9 Ų
Heavy Atom Count30
Formal Charge0
Complexity421
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Triheptanoin is a medium chain triglyceride indicated to provide calories and fatty acids to treat long chain fatty acid oxidation disorders (lc-FAODs).


FDA Label


5 Pharmacology and Biochemistry
5.1 Pharmacology

Triheptanoin is a source of medium chain fatty acids for patients with lc-FAODs. It has a moderate duration of action and a wide therapeutic window. Patients should be counselled regarding the risk of feeding tube dysfunction and intestinal malabsorption due to pancreatic insufficiency.


5.2 ATC Code

A - Alimentary tract and metabolism

A16 - Other alimentary tract and metabolism products

A16A - Other alimentary tract and metabolism products

A16AX - Various alimentary tract and metabolism products

A16AX17 - Triheptanoin


5.3 Absorption, Distribution and Excretion

Absorption

A single 0.3 g/kg dose of triheptanoin reaches a Cmax of 178.9 mol/L, with a Tmax 0.5 h, and an AUC of 336.5 mol\*h/L. A single 0.4 g/kg dose of triheptanoin reaches a Cmax of 259.1 mol/L, with a Tmax 0.8 h, and an AUC of 569.1 mol\*h/L.


Route of Elimination

Triheptanoin is minimally eliminated in the urine.


Clearance

A single dose of 0.3 g/kg results in a mean apparent clearance of 6.05 L/h/kg for heptanoate. A single dose of 0.4 g/kg results in a mean apparent clearance of 4.31 L/h/kg for heptanoate.


5.4 Metabolism/Metabolites

Triheptanoin is hydrolysed to heptanoate, which can be further metabolized to -hydroxypentanoate or -hydroxybutyrate.


5.5 Biological Half-Life

Due to multiple peak concentrations of the heptanoate metabolite, the half life of triheptanoin could not be determined.


5.6 Mechanism of Action

Triheptanoin is a source of heptanoate fatty acids, which can be metabolized without the enzymes of long chain fatty acid oxidation. In clinical trials, patients with lc-FAODs treated with triheptanoin experienced improvements in hypoglycemia, cardiomyopathy, and rhabdomyolysis.


API SUPPLIERS

read-more
read-more

01

TAPI Technology & API Services

Israel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

Flag Israel
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT arrow-down
TAPI Company Banner

02

Country

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

03

Navinta

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Navinta

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

04

Teva Pharmaceutical Industries

Israel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Teva Pharmaceutical Industries

Israel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
blank

05

Ultragenyx Pharmaceutical

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Ultragenyx Pharmaceutical

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

06

Sun Pharmaceutical Industries Limi...

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Sun Pharmaceutical Industries Limi...

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
blank

07

Aurobindo Pharma Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PEGS Boston Summit
Not Confirmed
arrow

Aurobindo Pharma Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PEGS Boston Summit
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT arrow-down
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-moreread-more

01

PEGS Boston Summit
Not Confirmed

01

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2024-03-21

Pay. Date : 2024-01-25

DMF Number : 39430

Submission : 2024-02-08

Status : Active

Type : II

blank

02

Navinta Llc

U.S.A

USDMF

arrow
PEGS Boston Summit
Not Confirmed

02

Navinta Llc

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2024-04-16

Pay. Date : 2024-03-22

DMF Number : 39441

Submission : 2024-03-26

Status : Active

Type : II

blank

03

PEGS Boston Summit
Not Confirmed

03

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2024-04-16

Pay. Date : 2024-03-15

DMF Number : 39415

Submission : 2024-03-29

Status : Active

Type : II

blank

04

Tapi Nl Bv

Israel

USDMF

arrow
PEGS Boston Summit
Not Confirmed

04

Tapi Nl Bv

Israel
arrow
PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 39145

Submission : 2024-02-07

Status : Active

Type : II

blank

05

PEGS Boston Summit
Not Confirmed

05

PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 26895

Submission : 2013-03-01

Status : Active

Type : II

blank

06

Devi Pharmatech Private Ltd

Country

USDMF

arrow
PEGS Boston Summit
Not Confirmed

06

Devi Pharmatech Private Ltd

Country
arrow
PEGS Boston Summit
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2025-09-02

Pay. Date : 2025-07-09

DMF Number : 42237

Submission : 2025-07-06

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

Flag Israel
Digital Content Digital Content

TRIHEPTANOIN

NDC Package Code : 15894-0041

Start Marketing Date : 2024-01-03

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

TAPI Company Banner

02

PEGS Boston Summit
Not Confirmed
arrow
arrow
PEGS Boston Summit
Not Confirmed

TRIHEPTANOIN

NDC Package Code : 59651-938

Start Marketing Date : 2024-01-23

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (50kg/50kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

Flag Israel
Digital Content Digital Content

Triheptanoin

About the Company : Founded in 1935, TAPI Technology & API Services has a long legacy of advancing health through innovation. Today, we offer one of the industry’s most comprehensive API portfolios ...

Founded in 1935, TAPI Technology & API Services has a long legacy of advancing health through innovation. Today, we offer one of the industry’s most comprehensive API portfolios with over 350 products, alongside tailored CDMO services. Leveraging deep expertise and diverse technologies, we deliver flexible, high-quality solutions to meet our partners’ needs. Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.
TAPI Company Banner
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more
  • Development Update

Details:

Triheptanoin is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Medium chain acyl CoA dehydrogenase Deficiency.


Lead Product(s): Triheptanoin,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Ultragenyx Pharmaceutical

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 31, 2025

blank

01

Jerry Vockley

Country
arrow
PEGS Boston Summit
Not Confirmed

Jerry Vockley

Country
arrow
PEGS Boston Summit
Not Confirmed

Details : Triheptanoin is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Medium chain acyl CoA dehydrogenase Deficiency.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

July 31, 2025

blank

Details:

Triheptanoin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pyruvate Dehydrogenase Complex Deficiency Disease.


Lead Product(s): Triheptanoin,Inapplicable

Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Jirair Krikor Bedoyan

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 01, 2024

blank

02

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Triheptanoin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pyruvate Dehydrogenase Complex Deficiency Disease.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

April 01, 2024

blank

Details:

Triheptanoin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Medium chain acyl CoA dehydrogenase Deficiency.


Lead Product(s): Triheptanoin,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Jerry Vockley

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 05, 2023

blank

03

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Triheptanoin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Medium chain acyl CoA dehydrogenase Deficiency.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

October 05, 2023

blank

Details:

Triheptanoin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Long-chain Fatty Acid Oxidation Disorders.


Lead Product(s): Triheptanoin,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 06, 2023

blank

04

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Triheptanoin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Long-chain Fatty Acid Oxidation Disorders.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

July 06, 2023

blank

Details:

Orsini Pharmaceutical Services has been selected by Ultragenyx Pharmaceutical as a limited distribution specialty pharmacy partner for Dojolvi (triheptanoin). Dojolvi™ is indicated as a source of calories and fatty acids for the treatment of molecularly confirmed LC-FAOD.


Lead Product(s): Triheptanoin,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Dojolvi

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Ultragenyx Pharmaceutical

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership July 10, 2020

blank

05

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Orsini Pharmaceutical Services has been selected by Ultragenyx Pharmaceutical as a limited distribution specialty pharmacy partner for Dojolvi (triheptanoin). Dojolvi™ is indicated as a source of calories and fatty acids for the treatment of molecularl...

Product Name : Dojolvi

Product Type : Miscellaneous

Upfront Cash : Undisclosed

July 10, 2020

blank

Details:

Triheptanoin is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.


Lead Product(s): Triheptanoin,Inapplicable

Therapeutic Area: Undisclosed Brand Name: Undisclosed

Study Phase: UndisclosedProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 12, 2018

blank

06

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Triheptanoin is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

December 12, 2018

blank

Details:

Triheptanoin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Glycogen Storage Disease Type I.


Lead Product(s): Triheptanoin,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Areeg El-Gharbawy

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 11, 2018

blank

07

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Triheptanoin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Glycogen Storage Disease Type I.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

September 11, 2018

blank
  • Development Update

Details:

Triheptanoin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Glycogen Storage Disease Type VII.


Lead Product(s): Triheptanoin,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Ultragenyx Pharmaceutical

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 22, 2018

blank

08

Rigshospitalet

Country
arrow
PEGS Boston Summit
Not Confirmed

Rigshospitalet

Country
arrow
PEGS Boston Summit
Not Confirmed

Details : Triheptanoin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Glycogen Storage Disease Type VII.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

August 22, 2018

blank

Details:

Triheptanoin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Amyotrophic Lateral Sclerosis.


Lead Product(s): Triheptanoin,Inapplicable

Therapeutic Area: Neurology Brand Name: Undisclosed

Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous

Sponsor: Richard Bedlack, M.D., Ph.D.

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 24, 2018

blank

09

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Lead Product(s) : Triheptanoin,Inapplicable

Therapeutic Area : Neurology

Highest Development Status : Phase I/ Phase II

Partner/Sponsor/Collaborator : Richard Bedlack, M.D., Ph.D.

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Triheptanoin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Amyotrophic Lateral Sclerosis.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

April 24, 2018

blank

Details:

Triheptanoin is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Glut1 Deficiency Syndrome.


Lead Product(s): Triheptanoin,Inapplicable

Therapeutic Area: Genetic Disease Brand Name: Undisclosed

Study Phase: UndisclosedProduct Type: Miscellaneous

Sponsor: Jerry Vockley

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 21, 2016

blank

10

PEGS Boston Summit
Not Confirmed
PEGS Boston Summit
Not Confirmed

Details : Triheptanoin is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Glut1 Deficiency Syndrome.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

November 21, 2016

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Annual Reports

read-more
read-more

01

Brand Name : UX007

Triheptanoin

arrow
PEGS Boston Summit
Not Confirmed

Brand Name : UX007

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Triheptanoin

Main Therapeutic Indication : Rare Disorders

Currency : USD

2019 Revenue in Millions : 3

2018 Revenue in Millions : 1

Growth (%) : 163

blank

02

Brand Name : UX007

Triheptanoin

arrow
PEGS Boston Summit
Not Confirmed

Brand Name : UX007

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Triheptanoin

Main Therapeutic Indication : Rare Disorders

Currency : USD

2020 Revenue in Millions : 13

2019 Revenue in Millions : 3

Growth (%) : 295

blank

03

Brand Name : UX007

Triheptanoin

arrow
PEGS Boston Summit
Not Confirmed

Brand Name : UX007

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Triheptanoin

Main Therapeutic Indication : Rare Disorders

Currency : USD

2021 Revenue in Millions : 40

2020 Revenue in Millions : 13

Growth (%) : 204

blank

04

Brand Name : Dojolvi

Triheptanoin

arrow
PEGS Boston Summit
Not Confirmed

Brand Name : Dojolvi

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Triheptanoin

Main Therapeutic Indication : Rare Diseases

Currency : USD

2022 Revenue in Millions : 56

2021 Revenue in Millions : 40

Growth (%) : 41

blank

05

Brand Name : Dojolvi

Triheptanoin

arrow
PEGS Boston Summit
Not Confirmed

Brand Name : Dojolvi

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Triheptanoin

Main Therapeutic Indication : Rare Diseases

Currency : USD

2023 Revenue in Millions : 71

2022 Revenue in Millions : 56

Growth (%) : 27

blank

06

Brand Name : Dojolvi

Triheptanoin

arrow
PEGS Boston Summit
Not Confirmed

Brand Name : Dojolvi

U.S.A
arrow
PEGS Boston Summit
Not Confirmed

Triheptanoin

Main Therapeutic Indication : Rare Diseases and Disorders

Currency : USD

2024 Revenue in Millions : 88

2023 Revenue in Millions : 71

Growth (%) : 25

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 620-67-7 / Triheptanoin API manufacturers, exporters & distributors?

Triheptanoin manufacturers, exporters & distributors 1

62

PharmaCompass offers a list of Triheptanoin API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Triheptanoin manufacturer or Triheptanoin supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Triheptanoin manufacturer or Triheptanoin supplier.

API | Excipient name

Triheptanoin

Synonyms

620-67-7, Propane-1,2,3-triyl triheptanoate, Trienanthoin, Trioenanthoin, Glyceryl triheptanoate, Glycerol triheptanoate

Cas Number

620-67-7

Unique Ingredient Identifier (UNII)

2P6O7CFW5K

About Triheptanoin

Triheptanoin is a source of heptanoate fatty acids, which can be metabolized without the enzymes of long chain fatty acid oxidation. In clinical trials, patients with long chain fatty acid oxidation disorders (lc-FAODs) treated with triheptanoin are less likely to develop hypoglycemia, cardiomyopathy, rhabdomyolysis, and hepatomegaly. Complications in lc-FAOD patients are reduced from approximately 60% to approximately 10% with the addition of triheptanoin. Triheptanoin was granted FDA approval on 30 June 2020.

TRIHEPTANOIN ULTRAPURE Manufacturers

A TRIHEPTANOIN ULTRAPURE manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of TRIHEPTANOIN ULTRAPURE, including repackagers and relabelers. The FDA regulates TRIHEPTANOIN ULTRAPURE manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. TRIHEPTANOIN ULTRAPURE API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of TRIHEPTANOIN ULTRAPURE manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

TRIHEPTANOIN ULTRAPURE Suppliers

A TRIHEPTANOIN ULTRAPURE supplier is an individual or a company that provides TRIHEPTANOIN ULTRAPURE active pharmaceutical ingredient (API) or TRIHEPTANOIN ULTRAPURE finished formulations upon request. The TRIHEPTANOIN ULTRAPURE suppliers may include TRIHEPTANOIN ULTRAPURE API manufacturers, exporters, distributors and traders.

click here to find a list of TRIHEPTANOIN ULTRAPURE suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

TRIHEPTANOIN ULTRAPURE USDMF

A TRIHEPTANOIN ULTRAPURE DMF (Drug Master File) is a document detailing the whole manufacturing process of TRIHEPTANOIN ULTRAPURE active pharmaceutical ingredient (API) in detail. Different forms of TRIHEPTANOIN ULTRAPURE DMFs exist exist since differing nations have different regulations, such as TRIHEPTANOIN ULTRAPURE USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A TRIHEPTANOIN ULTRAPURE DMF submitted to regulatory agencies in the US is known as a USDMF. TRIHEPTANOIN ULTRAPURE USDMF includes data on TRIHEPTANOIN ULTRAPURE's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The TRIHEPTANOIN ULTRAPURE USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of TRIHEPTANOIN ULTRAPURE suppliers with USDMF on PharmaCompass.

TRIHEPTANOIN ULTRAPURE NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing TRIHEPTANOIN ULTRAPURE as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for TRIHEPTANOIN ULTRAPURE API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture TRIHEPTANOIN ULTRAPURE as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain TRIHEPTANOIN ULTRAPURE and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a TRIHEPTANOIN ULTRAPURE NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of TRIHEPTANOIN ULTRAPURE suppliers with NDC on PharmaCompass.

TRIHEPTANOIN ULTRAPURE GMP

TRIHEPTANOIN ULTRAPURE Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of TRIHEPTANOIN ULTRAPURE GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right TRIHEPTANOIN ULTRAPURE GMP manufacturer or TRIHEPTANOIN ULTRAPURE GMP API supplier for your needs.

TRIHEPTANOIN ULTRAPURE CoA

A TRIHEPTANOIN ULTRAPURE CoA (Certificate of Analysis) is a formal document that attests to TRIHEPTANOIN ULTRAPURE's compliance with TRIHEPTANOIN ULTRAPURE specifications and serves as a tool for batch-level quality control.

TRIHEPTANOIN ULTRAPURE CoA mostly includes findings from lab analyses of a specific batch. For each TRIHEPTANOIN ULTRAPURE CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

TRIHEPTANOIN ULTRAPURE may be tested according to a variety of international standards, such as European Pharmacopoeia (TRIHEPTANOIN ULTRAPURE EP), TRIHEPTANOIN ULTRAPURE JP (Japanese Pharmacopeia) and the US Pharmacopoeia (TRIHEPTANOIN ULTRAPURE USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty